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Introduction: Lambert–Eaton myasthenic syndrome is a rare disorder and it is known as a paraneoplastic
neurological syndrome. Small cell lung cancer often accompanies this syndrome. Lambert–Eaton myasthenic
syndrome associated with lung adenocarcinoma is extremely rare; there are only a few reported cases worldwide.
Case presentation: A 75-year-old Japanese man with a past history of chronic rheumatoid arthritis and Sjögren
syndrome was diagnosed with Lambert–Eaton myasthenic syndrome by electromyography and serum anti-P/Q-type
voltage-gated calcium channel antibody level preceding the diagnosis of lung cancer. A chest computed tomography
to screen for malignant lesions revealed an abnormal shadow in the lung. Although a histopathological examination
by bronchoscopic study could not reveal the malignancy, lung cancer was mostly suspected after the results of a chest
computed tomography and [18F]-fluorodeoxyglucose positron emission tomography. An intraoperative diagnosis
based on the frozen section obtained by tumor biopsy was adenocarcinoma so the patient underwent a lobectomy of
the right lower lobe and lymph node dissection with video-assisted thoracoscopic surgery. The permanent
pathological examination was the same as the frozen diagnosis (pT2aN1M0: Stage IIa: TNM staging 7th edition).
Immunohistochemistry revealed that most of the cancer cells were positive for P/Q-type voltage-gated calcium
channel.
Conclusions: Our case is a rare combination of Lambert–Eaton myasthenic syndrome associated with lung
adenocarcinoma, rheumatoid arthritis and Sjögren syndrome, and to the best of our knowledge it is the first report
that indicates the presence of voltage-gated calcium channel in lung adenocarcinoma by immunostaining.
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ImmunostainingIntroduction
Lambert–Eaton myasthenic syndrome (LEMS) is a rare
but well-known paraneoplastic disorder characterized by
muscle weakness and fatigability predominantly involving
the proximal lower limbs. Recently, measurement of serum
anti-P/Q-type voltage-gated calcium channel (VGCC) anti-
body level has been used, in addition to clinical manifesta-
tions and nerve conduction studies, to diagnose LEMS.
Patients with LEMS have mostly small cell lung cancer* Correspondence: hiromasa@jg7.so-net.ne.jp
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reproduction in any medium, provided the or(SCLC); other subtypes of lung cancer are extremely rare.
We present a rare case of LEMS associated with pulmon-
ary adenocarcinoma, chronic rheumatoid arthritis (RA)
and Sjögren syndrome (Sjs) and provide findings of the
resected specimen immunostained with P/Q-type VGCC.
Case presentation
The patient was a 75-year-old Japanese man with progres-
sive muscle weakness of his bilateral lower extremities
and gait disturbance. He was referred to the Department
of Neurology of our hospital for workup. His neurological
examination showed muscle weakness and atrophy of his
lower extremities, depressed deep tendon reflexes and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Chest computed tomography scan showing the
shadow of a solid mass with spiculation in the patient’s right
Segment 9b region, and emphysematous lung.
Arai et al. Journal of Medical Case Reports 2012, 6:281 Page 2 of 5
http://www.jmedicalcasereports.com/content/6/1/281autonomic dysfunction, that is, dry mouth and orthostatic
hypotension. His results for manual muscle strength testing
increased from 3 out of 5 to 4– out of 5 for his bilateral
lower extremities after a sustained 30-second contraction.
His sensation was intact to light touch, and pinprick and
Babinski’s sign were down-going bilaterally. A provocative
nerve conduction study on the ulnar nerve showed no
reduction after repetitive stimulation and tended to in-
crease at 15Hz of high-frequency stimulation (Figure 1).
Serum P/Q-type VGCC antibody level was elevated to
31.8pmol/L (cut-off point <20.0pmol/L [1]). Taken together
with clinical findings, we made a diagnosis of LEMS. A
chest abdominal computed tomography (CT) to screen
for malignant lesions revealed an abnormal shadow in
the right pulmonary lower lobe. He was then referred
to our department (Thoracic Surgery in Respiratory
Disease Center) for diagnosis and treatment of lung tumor.
The lung tumor with spiculation was located in
Segment 9b, with a maximum diameter of 30mm
(Figure 2). There was no lymphadenopathy or pleural
effusion. A CT of the patient’s chest showed a very bilateral
emphysematous lung. No abnormality was seen in his ab-
domen by CT or in the brain by enhanced magnetic reson-
ance imaging (MRI). A [18F]-fluorodeoxyglucose positron
emission tomography showed increased uptake of fluoro-
deoxyglucose in the mass region and right hilar region
(maximum standardized uptake values were 9.6 and 3.3,
respectively). Although a bronchoscopic examination did
not reveal malignancy, primary lung cancer was strongly
suspected.
The patient had worked as a carpenter before the onset
of muscle weakness. However, as his symptoms worsened,
he required assistance in daily life (performance status 2).
He was admitted to our ward by wheelchair. He had a
history of chronic RA medicated by oral prednisolone
therapy. He also complained of thirst for many months. A
full blood examination and biochemical examination wereFigure 1 Provocative nerve conduction study of patient’s ulnar
nerve showing a trend of increasing at 15Hz of high-frequency
stimulation.almost within the normal range. Carcinoembryonic antigen
was slightly elevated to 6.0ng/mL, whereas other tumor
markers for lung cancer (squamous cell carcinoma-related
antigen, sialylated Lewis X-i antigen, cytokeratin fragment,
neuron-specific enolase and progastrin-releasing peptide)
were within normal ranges. On screening for autoimmune
disease and collagen disease, serum CH50 was slightly
elevated to 46.7U/mL (normal range, 30 to 45), and
rheumatoid factor was within the normal range (10.4IU/mL;
normal range, 0 to 20). On screening for other collagen
diseases, anti-nuclear antibody was positive at the titer ofFigure 3 Microscopic findings of lung adenocarcinoma. The
lesion shows proliferation of infiltrating atypical epithelial cells with
cribriform or papillary structures, consistent with adenocarcinoma
(hematoxylin-eosin stain).
Figure 4 Most of the cancer cells are positive for P/Q-type
VGCC (immunohistochemistry).
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(normal range, 0–100). At this time it was clear that the
patient also had Sjs. He had a history of cigarette smok-
ing (40 cigarettes per day for 40 years). The preoperative
spirometry result was, %VC: 63.9% and FEV1.0% 76.0%;
and the blood gas analysis result was pCO2 38.9mmHg
and pO2 83.1mmHg (room air).
An operation was performed for a definite diagnosis and
treatment of the tumor. An intraoperative frozen diagno-
sis obtained by tumor biopsy revealed lung adenocarcin-
oma, and he underwent right lower lobe lobectomy and
lymph node dissection with video-assisted thoracoscopic
surgery. The operation took 230 minutes, with a blood
loss of 200mL. In the postoperative course, because of
prolonged air leakage from the remaining right pulmonary
lobes, tube drainage lasted for 9 days. Muscle weakness
gradually improved on approximately postoperative day 5,
and he could walk without assistance. Serum P/Q-typeTable 1 Characteristics of patients with Lambert–Eaton myast
Case
no.
Year First author Age Sex Site Histological
grade
1 1987 Ramos-Yeo [7] 56 M RLL Poor
2a 1989 Sumitomo [11] 58 M RML Poor
3a 1996 Okudera [12] 32 M RUL Poor
4 2008 Milanez [10] 66 M RUL Moderate
5 2012 This case
report
75 M RLL Moderate
a: English abstract only; DIC disseminated intravascular coagulation, DM dermatomy
RUL right upper lobe, Sjs Sjögren syndrome.VGCC antibody level was still elevated to 30.6pmol/L on
postoperative day 7. He underwent daily rehabilitation for
discharge. Approximately 2 months after the operation, he
had aspiration pneumonia with respiratory failure. Intub-
ation and respiratory management were performed in the
intensive care unit. He remains ventilator dependent at
4 months postoperation. Postoperative provocative nerve
conduction studies could not be performed.
His tumor was composed of a proliferation of infiltrating
atypical cells with cribriform or papillary structures. The
tumor measured 30mm in size and the diagnosis was
moderately-differentiated (G2) mixed-type adenocarcin-
oma (papillary and acinar adenocarcinoma) (Figure 3).
Lymph nodes metastases in the lung parenchyma were
noted. Pathological T2aN1M0 (Stage IIa: TNM staging 7th
edition) was diagnosed. Immunohistochemistry revealed
that most of the cancer cells were positive for P/Q-type
VGCC (Sigma-AldrichW; St. Louis, MO, USA) (Figure 4).
Discussion
LEMS is one of the representative paraneoplastic syn-
dromes and an autoimmune disease of the neuromuscular
junction. Because of its scarcity, the exact incidence of
LEMS is unknown. The prevalence of as few as 400 cases
in the USA in 1994 [2] and of 2 to 3 cases per million
inhabitants in the Netherlands in 2004 [3] has been
reported.
LEMS is known to be associated with malignant neo-
plasm, especially SCLC. Approximately 50 to 75% of
patients with LEMS have SCLC [2-7].
LEMS is also thought to be a complication of organ-
specific autoimmune diseases, such as thyroid disease, viti-
ligo, pernicious anemia, coeliac disease, and juvenile-onset
diabetes mellitus. However, systemic lupus erythematosus,
Sjs and RA associated with LEMS is rare; only a few cases






Death at 2 years
(due to infection)
None Lobectomy, Surviving at 2 years
adjuvant
chemotherapy
None Chemotherapy Death at 5 months
(due to DIC)
DM Lobectomy Death at 16 days
(due to sepsis)
RA, Sjs Lobectomy Surviving at
4 months
ositis, RA, rheumatoid arthritis, RLL right lower lobe, RML right middle lobe,
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ized by proximal muscle weakness affecting the legs
more than the arms, fatigability and dysautonomia. Ma-
lignant neoplasm usually occurs within the first 2 years
after the onset of LEMS and in almost all patients after
4 years [5]. Therefore, once LEMS is diagnosed or strongly
suspected, screening for malignant neoplasm, especially
SCLC (for example, using chest CT or tumor markers:
neuron-specific enolase and progastrin-releasing peptide),
is recommended. Moreover, careful observation and
screening should be required for at least 2 years [4-6]. The
treatment of SCLC controls its mortality and often results
in normalization of both electrodiagnostic findings and
clinical symptoms of LEMS [5,6].
The diagnosis of LEMS is established by clinical mani-
festation and by characteristic findings on nerve conduc-
tion studies. The nerve conduction study findings indicate
reduced amplitude of compound muscle action potential
that increases by over 100% after maximum voluntary
activation or 20 to 50Hz of nerve stimulation, and incre-
mental response (waxing) of compound muscle action po-
tential on the rapid rate of repetitive stimulation [5,6].
In the 1990s, Motomura and co-workers established a
new immunoassay of antibodies to VGCC for the diag-
nosis of LEMS [1]. VGCCs are situated on the presynaptic
nerve terminal and have a central role in the control of
neurotransmitter release [1,9]. Antibodies to VGCC inhibit
transmitter (acetylcholine) release at presynaptic nerve
terminals. It has been assumed that SCLC expresses func-
tional calcium channels and that autoantibodies to these
channels may cross-react with similar VGCCs [1,5,6,9].
Motomura [1] reported 85% of patients with LEMS to be
positive for VGCC and suggests that the titer of anti-P/Q-
type VGCC antibody in particular occupies an important
position in the diagnosis of LEMS; the remaining 15% of
patients were seronegative for VGCC [9]. In this subgroup,
SCLC is less common and the exact explanation of sero-
negative LEMS is still unknown. Thus, a negative antibody
titer of VGCC is not necessarily an indicator of the ab-
sence of LEMS [9].
LEMS is rarely associated with other subtypes of lung
cancer like adenocarcinoma. A PubMed literature search
(keywords, ‘Lambert-Eaton Myasthenic Syndrome’ and
‘lung adenocarcinoma’) found only two publications in the
English literature [7,10]. In Japan, although five cases have
been reported to date, there are only two reports of LEMS
associated with lung adenocarcinoma in Japanese research
with an English abstract [11,12]. The clinical features of
these five cases, including our case report, are summarized
in Table 1. The patients (all men) ranged from 32 to
75 years of age (mean age, 57± 16.0 years). Adenocarcin-
omas arose in the right lung in all cases. Coexistent colla-
gen diseases were recognized in two cases, including our
case (dermatomyositis, RA and Sjs). Three out of thesefive cases could undergo lung resection. Almost all LEMS
cases are related to SCLC, making them unsuitable for
resection. For cases not associated with SCLC, resection is
a possibility. Therefore, once LEMS is strongly suspected,
screening for malignancy and early detection of lung
carcinoma and its histological type is very important. Of
note, the histological differentiation of all demonstrated
cases was poor to moderate.
We examined P/Q-type VGCC expression immunohis-
tochemically using resected lung tumor sections. Most of
the neoplastic cells were stained positive, and the area
consisting of poorly-differentiated neoplastic cells tended
to show stronger signals. As far as we know, no report has
demonstrated immunohistochemical expression of VGCC
in neoplastic cells.
Conclusions
Taking together the results of immunostaining and the fact
that our patient also had collagen diseases (RA and Sjs),
autoimmune function may be related to the onset of
LEMS and, in the case of lung adenocarcinoma, lower-
differentiated cases appear to develop P/Q-type VGCC.
However, the actual mechanism by which anti-P/Q-type
VGCC antibody causes LEMS is unclear because the
experimental model of this rare disease has not been
established [6]. Further molecular biological studies are
required. Clinically, physicians must manage patients with
muscle weakness while considering LEMS as a differential
diagnosis. Recognition and awareness of this rare syn-
drome are essential for a better prognosis and quality of
life for these patients.
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